BGPT: Best Evidence: donor heart cold ischemic time survival multi-center

Explore by Goal

Quick Explanation Copied

The supplied evidence does not contain any multi-center donor heart cold ischemic time survival data, so the requested claim cannot be evaluated. The closest item is a small porcine preservation study showing troponin I release roughly tripled from 4-hour to 14-hour ischemia, partially mitigated by cariporide .

Long Explanation

Evidence Gap: No Multi-Center Human CIT-Survival Data Present

The records supplied do not include any multi-center study linking donor heart cold ischemic time (CIT) to survival. The query's premise cannot be supported or battle-tested from these sources. The only directly relevant quantitative evidence is a porcine allograft preservation study (42 pigs) reporting that initial troponin I release post-reperfusion rose from 210±52 at 4 hours to 633±177 mg/ml at 14 hours of storage, with cariporide reducing release to 68±21 and 346±93 respectively — a mechanistic ischemia-injury signal, but from animals, small n, and no survival endpoint .

Missing to actually answer the query: a multi-center human registry or trial dataset reporting CIT-stratified graft/recipient survival with effect sizes, confidence intervals, and covariate adjustment. None exists in the supplied records; the remaining studies concern amyloidosis heart transplant outcomes, lung/kidney preservation, and liver hemochromatosis — none provide donor heart CIT-survival estimates.

Feedback:

Updated: September 22, 2026

Top Data Sources Export MCP

1. This single-center, retrospective study evaluated intermediate-term (3-year) outcomes of heart transplantation in patients with cardiac amyloidosis (AL-CA and ATTR-CA) compared with non-amyloid restrictive cardiomyopathy, showing acceptable survival and no amyloid recurrence in the transplanted heart, with AL-CA showing numerically worse outcomes than ATTR-CA but the study not powered for subgroup differences. [2021]

7QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. This study investigates the relationship between the initial rate of troponin I release post-reperfusion and the effectiveness of myocardial protection during cardiac allograft preservation, demonstrating that shorter ischemic times and the use of cariporide significantly reduce troponin I release and improve early graft function. [2003]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. Induction/expression of Hsp70 dampens TNF-α production and NF-κB signaling in the myocardium, revealing a novel endogenous mechanism for protecting the heart from post-injury depression and suggesting preconditioning-based therapeutic strategies. [2002]

7QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

4. This study evaluates the effectiveness of Continuous Hypothermic Perfusion Preservation (CHPP) for renal grafts from non-heart-beating donors with prolonged warm ischemic time, reporting two successful transplant cases. [1997]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

5. Distal donor procurement for heart–lung and lung transplantation using a simple Collins-modified solution pulmonary-artery infusion at 4°C preserves the cardiopulmonary block for approximately 4–5 hours, yielding adequate postoperative oxygenation and discharge readiness in two distant human recipients. [1988]

2QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

Key Insight

Animal ischemia-reperfusion injury biomarkers scale steeply with ischemic duration, but translating that into human survival thresholds requires registry-scale multi-center data, which is absent here.

Keep Exploring

What is the dose-response relationship between donor heart cold ischemic time and 1-year graft survival in large multi-center human registries?

How does ex vivo machine perfusion of donor hearts modify the CIT-survival relationship in clinical trials?

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-rely on the completeness of supplied records and under-weight the possibility that relevant evidence exists outside them.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Evidence Gap: No Multi-Center Human CIT-Survival Data Present

Top Data Sources Export MCP

3. Induction/expression of Hsp70 dampens TNF-α production and NF-κB signaling in the myocardium, revealing a novel endogenous mechanism for protecting the heart from post-injury depression and suggesting preconditioning-based therapeutic strategies. [2002]

4. This study evaluates the effectiveness of Continuous Hypothermic Perfusion Preservation (CHPP) for renal grafts from non-heart-beating donors with prolonged warm ischemic time, reporting two successful transplant cases. [1997]

9. This study investigates the effect of surfactant treatment on graft function in a non-heart-beating donor rat lung transplantation model, demonstrating that surfactant improves arterial oxygen tension and reduces lipid peroxidation compared to untreated controls. [2001]

10. This study investigates the effect of overexpressing human superoxide dismutase (hSOD1) in a concordant xenograft model on ischemia-reperfusion injury and graft survival, finding no significant impact on rejection or graft function. [2001]

12. This study investigates the impact of donor smoking on pulmonary edema and biomarkers of inflammation and lung epithelial dysfunction in ex vivo donor lungs, revealing significant metabolic changes over time that may guide future lung transplantation outcomes. [2013]

Ask a Follow-Up

Key Insight

Animal ischemia-reperfusion injury biomarkers scale steeply with ischemic duration, but translating that into human survival thresholds requires registry-scale multi-center data, which is absent here.

Keep Exploring

What is the dose-response relationship between donor heart cold ischemic time and 1-year graft survival in large multi-center human registries?

How does ex vivo machine perfusion of donor hearts modify the CIT-survival relationship in clinical trials?

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-rely on the completeness of supplied records and under-weight the possibility that relevant evidence exists outside them.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Evidence Gap: No Multi-Center Human CIT-Survival Data Present

Top Data Sources ExportMCP

3. Induction/expression of Hsp70 dampens TNF-α production and NF-κB signaling in the myocardium, revealing a novel endogenous mechanism for protecting the heart from post-injury depression and suggesting preconditioning-based therapeutic strategies. [2002]

4. This study evaluates the effectiveness of Continuous Hypothermic Perfusion Preservation (CHPP) for renal grafts from non-heart-beating donors with prolonged warm ischemic time, reporting two successful transplant cases. [1997]

9. This study investigates the effect of surfactant treatment on graft function in a non-heart-beating donor rat lung transplantation model, demonstrating that surfactant improves arterial oxygen tension and reduces lipid peroxidation compared to untreated controls. [2001]

10. This study investigates the effect of overexpressing human superoxide dismutase (hSOD1) in a concordant xenograft model on ischemia-reperfusion injury and graft survival, finding no significant impact on rejection or graft function. [2001]

12. This study investigates the impact of donor smoking on pulmonary edema and biomarkers of inflammation and lung epithelial dysfunction in ex vivo donor lungs, revealing significant metabolic changes over time that may guide future lung transplantation outcomes. [2013]

Ask a Follow-Up

Key Insight

Animal ischemia-reperfusion injury biomarkers scale steeply with ischemic duration, but translating that into human survival thresholds requires registry-scale multi-center data, which is absent here.

Keep Exploring

What is the dose-response relationship between donor heart cold ischemic time and 1-year graft survival in large multi-center human registries?

How does ex vivo machine perfusion of donor hearts modify the CIT-survival relationship in clinical trials?

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-rely on the completeness of supplied records and under-weight the possibility that relevant evidence exists outside them.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP